Clinical Drug Investigation

, Volume 34, Issue 8, pp 587–591 | Cite as

Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder

  • Pablo RoitmanEmail author
  • Raphael Mechoulam
  • Rena Cooper-Kazaz
  • Arieh Shalev
Short Communication


Background and Objectives

Many patients with post-traumatic stress disorder (PTSD) achieve but partial remission with current treatments. Patients with unremitted PTSD show high rates of substance abuse. Marijuana is often used as compassion add-on therapy for treatment-resistant PTSD. This open-label study evaluates the tolerance and safety of orally absorbable Δ9-tetrahydrocannabinol (THC) for chronic PTSD.


Ten outpatients with chronic PTSD, on stable medication, received 5 mg of Δ9-THC twice a day as add-on treatment.


There were mild adverse effects in three patients, none of which led to treatment discontinuation. The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms.


Orally absorbable Δ9-THC was safe and well tolerated by patients with chronic PTSD.


Sleep Quality Ptsd Symptom Duloxetine Anandamide Pittsburgh Sleep Quality Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Raphael Mechoulam has consulted to GW Pharmaceuticals, UK.


  1. 1.
    Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr. 2009;14(1 Suppl 1):25–31.PubMedGoogle Scholar
  2. 2.
    Bonn-Miller MO, Vujanovic AA, Drescher KD. Cannabis use among military veterans after residential treatment for posttraumatic stress disorder. Psychol Addict Behav. 2011;25(3):485–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012;4(7–8):649–59.PubMedCrossRefGoogle Scholar
  5. 5.
    Pierre JM. Psychosis associated with medical marijuana: risk vs. benefits of medicinal cannabis use. Am J Psychiatry. 2010;167(5):598–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Musty RE, Rossi R. Effects of smoked Cannabis and oral delta-9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. J Cannabis Therapy. 2001;1:30.CrossRefGoogle Scholar
  7. 7.
    Crippa JA, Zuardi AW, Martin-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24(7):515–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, et al. Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007;45(5):545–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoact Drugs. 2014;46(1):73–7.CrossRefGoogle Scholar
  11. 11.
    Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Rabinak CA, Angstadt M, Sripada CS, Abelson JL, Liberzon I, Milad MR, et al. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology. 2013;64:396–402.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):6.Google Scholar
  14. 14.
    Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Guy GW. The Clinical Global Impression Scale. In: ECDEU assessment manual for psychopharmacology–revised. Bethesda; US Department of Health, Education and Welfare; 1976: pp 218–222.Google Scholar
  16. 16.
    Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.PubMedCrossRefGoogle Scholar
  17. 17.
    Krakow B. Nightmare frequency in sexual assault survivors with PTSD. J Anxiety Disord. 2002;16(2):175–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Krakow B, Hollifield M, Schrader R, Koss M, Tandberg D, Lauriello J, et al. A controlled study of imagery rehearsal for chronic nightmares in sexual assault survivors with PTSD: a preliminary report. J Trauma Stress. 2000;13(4):589–609.PubMedCrossRefGoogle Scholar
  19. 19.
    Guy GW. A phase 1, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannabis Ther 2003;3:31.Google Scholar
  20. 20.
    Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349–53.PubMedCrossRefGoogle Scholar
  21. 21.
    Haroutiunian S, Rosen G, Shouval R, Davidson E. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. J Pain Palliat Care Pharmacother. 2008;22(3):213–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt Int. 2012;109(29–30):495–501.Google Scholar
  23. 23.
    Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;1(136):162–5.CrossRefGoogle Scholar
  24. 24.
    Schierenbeck T, Riemann D, Berger M, Hornyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12(5):381–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Bremner JD, Southwick SM, Darnell A, Charney DS. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. Am J Psychiatry. 1996;153(3):369–75.PubMedGoogle Scholar
  26. 26.
    Ursano RJ, Zhang L, Li H, Johnson L, Carlton J, Fullerton CS, et al. PTSD and traumatic stress from gene to community and bench to bedside. Brain Res. 2009;26(1293):2–12.CrossRefGoogle Scholar
  27. 27.
    Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011;124(4):250–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Pablo Roitman
    • 1
    • 5
    Email author
  • Raphael Mechoulam
    • 2
  • Rena Cooper-Kazaz
    • 3
  • Arieh Shalev
    • 1
    • 4
  1. 1.Department of PsychiatryHadassah Hebrew University Medical CenterJerusalemIsrael
  2. 2.Institute for Drug ResearchHebrew University School of PharmacyJerusalemIsrael
  3. 3.Psychiatry DepartmentClalit Health ServicesJerusalemIsrael
  4. 4.Department of Psychiatry, Steven and Alexandra Cohen Veterans Center for the Study of Post-Traumatic Stress and Traumatic Brain InjuryNew York University Langone Medical CenterNew YorkUSA
  5. 5.Mate YehudaIsrael

Personalised recommendations